Abstract

Subtypes of B cell non-Hodgkin’s lymphomas, including follicular lymphomas, have shown a unique high oligomannose presentation on their immunoglobulins that will interact with natural receptors of the innate immunity, reportedly causing stimulation and proliferation. From deep sequencing of the variable heavy and light chain sequences of follicular lymphoma involved tissue sections, we identified the consensus variable sequences possessing glycosylation sites at the complementarity determining region. Using this information, we developed a cell line, referred to here as BZ, which displays the consensus variable segments as part of a surface antibody (IgM) and confirmed its presentation of high oligomannose on the heavy chain both in vitro and in vivo. An mCherry expressing variant provided a reporter cell line displaying the high oligomannose surface biomarker while affording clear fluorescent signals for FACS screening as well as for fluorescent in vivo imaging of ectopic xenograft tumors. In developing this reporter cell line that displays the biomarker glycan of follicular lymphoma, we provide a tool that may be used for future screening and validation of receptive moieties for selectively binding high oligomannose for development of targeted diagnostics or therapeutics to such B cell malignancies that display this unique glycan.

Highlights

  • Subtypes of B cell non-Hodgkin’s lymphomas, including follicular lymphomas, have shown a unique high oligomannose presentation on their immunoglobulins that will interact with natural receptors of the innate immunity, reportedly causing stimulation and proliferation

  • Recent works have shown that glycosylation of the Ig of follicular lymphoma B cells results in presentation of oligomannose on the complementarity determining region (CDR) that is a necessary characteristic for their survival, as this glycosylation facilitates continual stimulatory interactions via the endogenous lectins in the surrounding tumor m­ icroenvironment[3,4]

  • We first carried out deep sequencing of the Ig variable regions of follicular lymphoma (FL) involved lymph node sections, where we identified a conserved glycosylation site presented at the third complementarity determining region (CDR3) of the variable heavy chain

Read more

Summary

Introduction

Subtypes of B cell non-Hodgkin’s lymphomas, including follicular lymphomas, have shown a unique high oligomannose presentation on their immunoglobulins that will interact with natural receptors of the innate immunity, reportedly causing stimulation and proliferation. Recent works examining the Ig variable regions of a large cohort of follicular lymphoma (FL) patients has shown an interesting common trait of presentation of a glycosylation site sequence within the variable segment, typically at the complementarity determining region (CDR)[4,7,8] This site has been previously reported in the variable heavy chain of B-cell receptors of at least 90% of FL patients and at least 41% of Diffuse Large B-Cell Lymphoma (DLBCL) ­patients[1,2,4,8,9], where such N-linked glycosylation sites of the CDR results in the unique display of a high oligomannose glycan. The potential use of this reporter cell line for in vitro screening or in vivo imaging studies may serve as a starting point toward identifying relevant high oligomannose receptors that may eventually be advanced into clinically useful probes

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call